Spirapril

Routes of
administrationOralATC codeLegal statusLegal status Pharmacokinetic dataBioavailability50%Metabolismconverted to spiraprilatElimination half-life30 to 35 hoursExcretionHepatic and renalIdentifiersCAS NumberPubChem CIDIUPHAR/BPSDrugBankChemSpiderUNIIKEGGChEBIChEMBLCompTox Dashboard (EPA)Chemical and physical dataFormulaC₂₂H₃₀N₂O₅S₂Molar mass466.61 g·mol⁻¹3D model (JSmol) ^NY (what is this?)  (verify)

Spirapril, sold under the brand name Renormax among others, is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ACE inhibitors.^{[citation needed]}

It was patented in 1980 and approved for medical use in 1995.^[1]

Chemistry

Like many ACE inhibitors, this prodrug is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment.^[2] However, data on its effect upon the renal function are conflicting.^[3]

References

External links

• Media related to Spirapril at Wikimedia Commons